Nuvectis Pharma prices 5 million-share offering at $20, raising $100 million

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCT

0.00
  • Nuvectis priced an underwritten public offering of 5,000,000 common shares at USD 20 per share.
  • Gross proceeds expected at USD 100 million; closing targeted for about July 1, 2026.
  • Underwriters hold a 30-day option to buy up to 750,000 additional shares.
  • Net proceeds earmarked for NXP100, NXP200, NXP900 development, added headcount, capital spending, public-company costs, general corporate purposes.
  • Cantor is sole bookrunner.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606292230PRIMZONEFULLFEED9754538) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.